Eagle Pharmaceuticals (Nasdaq: EGRX) (“Eagle” or the “Company”) announced that the U.S. District Court for the District of Delaware held that Eagle’s proposed vasopressin product does not infringe any of the patents Par asserted against the Company.
Eagle is first to file an Abbreviated New Drug Application (“ANDA”) referencing Vasostrict®, which had total U.S. sales of $786 million in 2020. In May 2018, Par sued Eagle for infringement of several patents. The trial was held in July 2021. The Court heard Par’s argument as to why Eagle’s proposed product would infringe its patents, as well as Eagle’s arguments as to why Par’s patents are both invalid and unenforceable.
The Court ruled that Par failed to meet its burden of proving that Eagle’s product would infringe any of the asserted patent claims. The opinion did not address Eagle’s invalidity or unenforceability claims.
“We are delighted with this decision,” stated Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals. “This is an important step toward giving the public a generic alternative to Vasostrict. We look forward to making our vasopressin product available soon.”
About Eagle Pharmaceuticals, Inc.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include RYANODEX®, BENDEKA®, BELRAPZO®, and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.